Raf we are definitely in uncharted territory.
Part of that IMO is somehow a small biotech company still has the rights to possibly the biggest blockbuster drug of all time. The big boys do not like this at all.
99.5% of the time, these small biotechs get bought out by the giants. The other .5% GIA successfully and become BP themselves.
Lipitor added over 100B in MCAP to PFE stock from 1996-2000. After people realized sales were peaking it started it’s dramatic decline. That’s how powerful one drug can be to a company.
If AMRN is able to pull this off GIA, successfully, worldwide, it will join the ranks of BP and will start acquiring other companies to bolster it’s pipeline and portfolio. This is what I want the most.